This presentation revisits the AAPS recommendations paper on validating LC-MS bioanalytical methods for protein therapeutics. Find out how the application of LC-MS techniques to the bioanalysis of protein therapeutics in support of regulated studies has progressed over the last three years since the paper's original publication date.
You will also learn about future predictions and notable trends in drug development from discovery to clinical trials, such as the drive to understand and improve assay selectivity and specificity.
At IQVIA Laboratories, our scientists have extensive bioanalytical method development and liquid chromatography - tandem mass spectrometry expertise to not only meet your analytical needs, but to bring insights to the table that enhance the drug development process. Download the presentation to learn more.
Speaker:
Stephen Lowes, Ph.D., Senior Scientific Director, Bioanalysis and ADME Services
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
High Throughput ADME Screening Services
Capabilities that accelerate preclinical studies
IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk
DDI Fact Sheet
